Skip to content
Brand AI

Beilu Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2025

    Selected Iopamidol in Centralized Procurement Rated Dishonest by Hebei for Late Delivery

    Beilu Pharmaceutical's selected product in the seventh national centralized procurement, iopamidol injection, was not delivered in a timely or adequate manner in Hebei. In June 2025, the Hebei Medical Drugs and Devices Centralized Procurement Center notified seven pharmaceutical companies including Livzon Group and Beilu Pharmaceutical and rated them at the "general" dishonesty level. The dishonesty rating may lead to reminders, risk warnings and listing restrictions, with appeal and repair possible.

    Source